Vivoryon Therapeutics N.V. · EURONEXT:VVY
Vivoryon Therapeutics — Technical Presentation (February 2025)
44 slides from Vivoryon Therapeutics's technical presentation, Feb 18, 2025
Slide 1: Changing Outcomes in Kidney Disease
Changing Outcomes in Kidney Disease Virtual R&D Update with KOL Speakers February 18, 2025 Vivoryon Therapeutics N.V.
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 3: Speakers
Anne Döring, CFA Host CFO Vivoryon Therapeutics Tobias Huber, MD Director III. Department of Medicine UKE Hamburg-Eppendorf Michael Schaeffer, PhD SPEAKERS CBO Vivoryon Therapeutics Kevin Carroll, PhD CEO KJC Statistics Frank Weber, MD CEO Vivoryon Therapeutics
Slide 4: Anne Döring, CFA
Anne Döring, CFA CFO Vivoryon Therapeutics
Slide 5: Inhibiting QPCTL has potential to halt the progressive course of kidney disease
Inhibiting QPCTL has potential to halt the progressive course of kidney disease through unique approach to tackle inflammation and fibrosis Huge unmet Current treatments do not stabilize / improve kidney function medical need leaving significant risk of ESRD (dialysis, transplant) or cardiovascular
Slide 6: Tobias B. Huber, MD
Tobias B. Huber, MD Chair of the Center of Internal Medicine and Director of the III. Department of Medicine, University Medical Center Hamburg-Eppendorf (UKE)
Slide 7: New scientific results of varoglutamstat in kidney disease
New scientific results of varoglutamstat in kidney disease Tobias B. Huber | 18th February 2025
Slide 8: Disclosures
Disclosures Consultancy agreements: Alexion, AstraZeneca, Bayer, Beren Therapeutics, Boehringer-Ingelheim, DaVita, Euroimmun, Fresenius Medical Care, Nipoka, Novartis, Pfizer, Renovate, Retrophin-Travere, Sanofi, Vera Therapeutics, Vifor, Vivoryon Therapeutics Research funding: Amicus Therapeutics,
Slide 9: Two independent randomized double-blind placebo-controlled Phase 2 studies
Vivoryon has evaluated varoglutamstat’s effect on kidney function in two independent randomized double-blind placebo-controlled Phase 2 studies Similarities and differences between VIVIAD and VIVA-MIND studies Parameter VIVIAD (Europe) VIVA-MIND (U.S.) Patient selection Mild AD, mean age 68 yrs Mild
Slide 10: VIVIAD and VIVA-MIND both show significant improvement in eGFR
VIVIAD and VIVA-MIND both show a statistically significant and clinically meaningful improvement in eGFR over baseline eGFR results (MDRD); all patients randomized to 600 mg BID varoglutamstat (v) and placebo (p) 7 6 eGFR treatment effect varoglutamstat vs eGFR treatment effect: 5 p=0.004 placebo mL
Slide 11: Consistent improvement in kidney function across treatment periods
Consistent improvement in kidney function and effect size across distinct treatment periods in both studies Sensitivity analysis; all patients randomized to 600 mg BID varoglutamstat (v) and placebo (p) 7 p=0.003 eGFR treatment effect varoglutamstat vs 6 6.21 eGFR treatment effect: p=0.01 p=0.001 pl
Slide 12: Treatment effect with and without diabetes
Results are nearly identical between studies when comparing treatment effect in patients with or without diabetes, with consistently higher effect in diabetes Subgroup analysis; with and without diabetes; 600 mg BID varoglutamstat (v) and placebo (p) 10 9 eGFR treatment effect varoglutamstat vs 8 eG
Slide 13: Strong efficacy signal in patients with diabetes
Consistent and very strong efficacy signal and large treatment effect observed in both studies in patients with diabetes at different timepoints Subgroup analysis; patients with diabetes; 600 mg BID varoglutamstat (v) and placebo (p) 10 9 9.41 eGFR treatment effect varoglutamstat vs 8 8.85 eGFR trea
Slide 14: Responder analysis of kidney function
Responder analysis: kidney function predominantly improved or stabilized in varoglutamstat treated patients compared to a decline in the placebo group Diabetes patients pooled VIVIAD & VIVA-MIND 100 % % patients with eGFR response of improving, stable 90% 22% Classification of eGFR response 80% 38%
Slide 15: Sensitivity analysis: responder analysis in diabetes patients
Sensitivity analysis: side by side comparison of responder analysis in diabetes patients shows high consistency between studies in diabetes patients Placebo 600 mg varoglutamstat 100 % 100 % 90% 90% 18% 29% 80% 80% 9% 70% 70% 67% 60% 80% 60% 50% 50% 40% 40% 73% 71% 30% 8% 30% 20% 20% 25% 10% 20% 10%
Slide 16: Localization of QC in human kidney organoids
Localization of QC in human kidney organoids
Slide 17: Significant need for therapies that can stabilize / improve kidney function
Significant need for therapies that can stabilize / improve kidney function Inhibition of QPCTL represents a novel target to address unmet needs in kidney disease Need ◆ Current standard of care reduces risk of CKD progression by approx. 1/3 ◆ Significant remaining risk of disease progression or pre
Slide 18: Michael Schaeffer, PhD
Michael Schaeffer, PhD CBO Vivoryon Therapeutics
Slide 19: A convenient new treatment option to fill the existing gap in kidney diseases
A convenient new treatment option to fill the existing gap in kidney diseases Varoglutamstat has the potential to stabilize/counteract continuous decline in kidney function Single agent oral compound First-in-class mechanism of action addressing key pathways in inflammation / fibrosis Statistically
Slide 20: Inhibition of QPCTL reduces kidney inflammation and fibrosis
Groundbreaking discovery: Inhibition of QPCTL reduces kidney inflammation and fibrosis, and improves pathophysiology and kidney function impaired kidney QPCTL inhibition improved kidney leads to reduction Varoglutamstat in potent pro- inflammatory and pyroglutamate substrate protein fibrotic peptide
Slide 21: Inhibition of QPCTL decreases pro-inflammatory cytokines and kidney fibrosis
Robust evidence demonstrating inhibition of intracellular QPCTL decreases activity of pro-inflammatory cytokines and kidney fibrosis 50 40 25 20 0 0 Kid ney Co l III Kidney α-SMA (% fractio nal area) (% fractional area) Decrease of pE-CCL2 levels by QPCT/L Histological changes show improvement Media
Slide 22: Varoglutamstat well-positioned in competitive landscape
Vivoryon’s varoglutamstat is well-positioned in competitive landscape Stabilizing or improving eGFR Varoglutamstat Key characteristics Varoglutamstat oral REACT Autologous Cell Therapy oral Ph2 Ph3 Slowed/continued Novel MoA decline of eGFR First-in-class QPCTLi or no eGFR data Bremelanotide s.c, no
Slide 23: Initial target market represents an attractive patient opportunity
Initial target market represents an attractive patient opportunity with potential label expansion to earlier stages of DKD / CKD ~70-75M3 Diabetes patients US & EU ~25-30M4 DKD patients (CKD + Diabetes) ~3-6M4 DKD patients Stage 3b/4 Total prevalent population 1International Diabetes Federation (IDF
Slide 24: New compound VY2149 shows improved uptake and PK profile
New development compound VY2149 shows improved cellular uptake, PK profile and superior outcomes in kidney animal studies Key PK Parameters1 10 9 8 7 ◆ Higher intracellular QPCTL inhibition translates to better 6 5 activity, lower doses and the opportunity for once daily 4 dosing 3 2 1 ◆ Pre-clinica
Slide 25: Pipeline focused on kidney disorders and inflammatory/fibrotic diseases
Pipeline focused on kidney disorders and inflammatory/fibrotic diseases Program Approach Discovery Preclinical Phase 1 Phase 2 Phase 3 Status DKD SMI POC in VIVIAD & VIVA-MIND results Preparing for Phase 2b DKD study (Varoglutamstat/PQ912) QPCT/L Inflammatory/fibrosis Kidney orphan diseases SMI Pre-
Slide 26: Kevin Carroll, PhD
Kevin Carroll, PhD CEO KJC Statistics
Slide 27: Statistical considerations of varoglutamstat's effect on eGFR
Statistical considerations of varoglutamstat’s effect on eGFR Kevin Carroll, PhD www.KJCStatistics.com 27
Slide 28: Meta-Analysis VIVIAD & VIVA-MIND
Meta-Analysis VIVIAD & VIVA-MIND • Small N per trial, obvious approach is to combine the data via meta-analysis • Not simple ‘pooling’, but stratified combination of treatment effects across trials • Trial estimates are denoted 𝜃!! ~ 𝑁(𝜃, 𝑣! ) • Fixed Effects Meta-Analysis [Homogeneity of…
Slide 29: Meta-Analysis, Diabetic Subjects
Meta-Analysis, Diabetic Subjects N N Treatment Effect & 95% CI Interaction Time Period Trial Placebo Varoglutamstat P-value (mL/min/1.73m2) P-value 600 mg VIVA-MIND 8 8 3.548 (-3.773, 10.869) 0.3232 0.3451 VIVIAD 12 11 -2.539 (-13.46, 8.378 ) 0.6415 0.3451 Weeks 04-16 Fixed 20 19 1.756 (-4.003, 7.51
Slide 30: Meta-Analysis: subgroups with risk factors for CKD
Meta-Analysis All subjects and subgroups with risk factors for CKD eGFR calculated with creatinine laboratory measurements as per protocol with MDRD formula www.KJCStatistics.com 30
Slide 31: Meta-Analysis: subgroups without risk factors for CKD
Meta-Analysis All subjects and subgroups without risk factors for CKD eGFR calculated with creatinine laboratory measurements as per protocol with MDRD formula www.KJCStatistics.com 31
Slide 32: Meta-Analysis Sensitivity Analysis: CKD-EPI remeasured creatinine
Meta-Analysis Sensitivity Analysis: CKD-EPI remeasured creatinine eGFR calculated with creatinine laboratory measurements performed after completion of the study with retained samples when available: remeasured; CKD-EPI formula www.KJCStatistics.com 32
Slide 33: Phase II PoC Design in Diabetic Subjects
Phase II PoC Design in Diabetic Subjects • Combined Study data for eGFR give : § Residual Error Variance 103 {mL/min/m2}2 § Auto correlation = 0.43 § SD mean eGFR over 18-24 weeks = 7.6 mL/min/m2 • PoC Design • N=40 per arm • Primary Endpoint = average eGFR over 18-24 weeks § Assessment of eGFR @ 18
Slide 34: Phase III Design in Diabetic Subjects
Phase III Design in Diabetic Subjects • Endpoint: eGFR slope over 2 years • VIVIAD data give: § Between slope variance component = 32.15 {mL/min/m2}2 § Residual variance component after regression = 70.4 {mL/min/m2}2 • eGFR measured every 2 months • N=150 per arm provides 90% power to test the hypot
Slide 35: Frank Weber, MD
Frank Weber, MD CEO Vivoryon Therapeutics
Slide 36: Safety: pooled analysis of VIVIAD and VIVA-MIND
Safety: pooled analysis of VIVIAD and VIVA-MIND 600 mg varoglutamstat is well tolerated All patients randomized to 600 mg varoglutamstat BID and placebo 90 80 70 % of patients with an event 60 50 40 30 20 10 0 TEAE TEAE related SAE SAE related Study Drug Discontinued Varoglutamstat 600 mg BID N=113
Slide 37: Pooled safety analysis: TEAE by system organ class
Pooled safety analysis VIVIAD and VIVA-MIND: TEAE by system organ class All patients randomized to 600 mg varoglutamstat BID and placebo All events independent of relationship assessment Infections and infestations Gastrointestinal disorders Nervous system disorders Psychiatric disorders Musculoskel
Slide 38: Additional health benefits observed in VIVA-MIND at week 72
Additional health benefits observed in VIVA-MIND (total population*) at week 72 Effects on weight loss, blood pressure and liver enzymes show same trends as in VIVIAD Change from baseline in Change from baseline in Change from baseline in liver transaminases (IU/L) weight (kg) blood pressure (mmHg)
Slide 39: Phase 2b study objectives and timelines
Phase 2b study objectives and timelines Primary Objective: Secondary Objectives Investigate the efficacy and Explore the efficacy of a once daily dose of varoglutamstat safety of varoglutamstat on Generate further evidence of the mechanism of action kidney function in patients with Generate data on
Slide 40: Phase 2b study design in patients with T2DM and CKD
Double-blind placebo-controlled Phase 2b study in patients with T2DM and CKD stages 3b and worse on top of standard of care (SoC)1 Draft trial design based on robust data from VIVA-MIND and Phase 2 meta-analysis End of Phase 2b Safety follow up Randomization (up to 6 weeks) Placebo PRIMARY (1:1, N =
Slide 41: QPCTL inhibitors have a large market potential
QPCTL inhibitors have a large market potential: Development opportunities across a range of diseases driven by underlying inflammation / fibrosis DKD / CKD / Rare kidney Disorders progressing through earlier stages diseases inflammation & fibrosis Replication of a sustained e.g. Alport / Fabry disea
Slide 42: Vivoryon: Poised to improve kidney health with varoglutamstat
Vivoryon: Poised to improve kidney health with varoglutamstat’s novel mechanism of action and breakthrough clinical study results Unique oral asset with Compelling Phase 2 Actionable, risk- MOA targeting results replicated in two contained plan for inflammation independent studies Phase 2b study in
Slide 43: Q&A
Q&A
Slide 44: Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale), Germany Munich Franz-Josef-Delonge-Str. 5 81249 München, Germany IR@vivoryon.com +49 (0)345 555 99 00 www.vivoryon.com
Vivoryon Therapeutics — Technical Presentation (February 2025) on 6ix